Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells
Felix C. E. Vogel(German Cancer Research Center), Alexander Roesch(Essen University Hospital), Susanne Horn(Vrije Universiteit Brussel), Christoph Magnes(Joanneum Research), Batool Shannan(Vrije Universiteit Brussel), Dirk Schadendorf(National Center for Tumor Diseases), Marija Trajkovic‐Arsic(German Cancer Research Center), Jens T. Siveke(German Cancer Research Center), Natalie Bordag(Joanneum Research), Elmar Zügner(Joanneum Research), Heike Chauvistré(Essen University Hospital), Renáta Váraljai(Vrije Universiteit Brussel)
Cited by 36
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k